Entera Bio Ltd. ENTX
Regular-session close
After hours · Nov 20, 6:39 PM ET
- YTD
- +70.36%
- 1 year
- +28.10%
5D -0.03 (-0.94%)
- Market cap
- 575.53M
- Revenue (ttm)
- 99.00K
- EPS (ttm)
- -0.40
- Shares out
- 36.83M
- Forward P/E
- -3.64
- YTD return
- +70.36%
- 1-year return
- +28.10%
- Volume
- 469.13K
- Avg volume
- 437.92K
- Open
- 3.25
- Previous close
- 3.28
- Day's range
- 3.18 – 3.32
- 52-week range
- 1.00 – 3.92
- Price target
- 10.00 (+202.6%)
Key statistics
- 50-day average
- 1.84
- 200-day average
- 1.90
- Enterprise value
- 70.74M
- Price / sales
- 744.08
- Price / book
- 10.99
- Free cash flow
- -6.34M
- Total cash
- 6.92M
- Total debt
- 309.00K
- Return on equity
- -144.67%
- Short % of float
- 0.19%
Fundamental scorecard
4 of 25 checks passed on ENTX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.05 | -0.08 | -0.03 | -60.00% |
| Aug 9, 2024 | Jun 1, 2024 | -0.06 | -0.06 | 0.00 | 0.00% |
| Aug 9, 2024 | Jun 1, 2024 | -0.06 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -0.06 | -0.05 | +0.01 | +16.67% |
| May 10, 2024 | Mar 1, 2024 | -0.06 | — | — | — |
| Mar 8, 2024 | Dec 1, 2023 | -0.08 | -0.07 | +0.01 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- enterabio.com
News
Your note
Sign in to keep a note on ENTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELLIS SEAN | Director | Stock Award(Grant) | Oct 1, 2024 | 127,627 |
| GALITZER HILLEL M.D. | Chief Operating Officer | Stock Award(Grant) | Apr 18, 2024 | 64,257 |
| LIEBERMAN GERALD M | Director | Stock Award(Grant) | Oct 1, 2024 | 290,291 |
| MALCA YONATAN | Director | Stock Award(Grant) | Oct 1, 2024 | 39,043 |
| OSTROV GERALD M | Director | Stock Award(Grant) | Oct 1, 2024 | 38,898 |
| TAITEL HAYA | Director | Stock Award(Grant) | Oct 1, 2024 | 57,728 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Knoll Capital Management, LLC | 10.54% | 3,881,879 | 7.76M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 1.76% | 648,600 | 1.30M | Sep 29, 2024 |
| Parkman Healthcare Partners LLC | 1.12% | 411,076 | 822.15K | Sep 29, 2024 |
| UBS Group AG | 0.39% | 142,747 | 285.49K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.17% | 61,200 | 122.40K | Sep 29, 2024 |
| Signature Estate & Investment Advisors, LLC | 0.13% | 47,328 | 94.66K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 17,597 | 35.19K | Oct 30, 2024 |
